The clinical investigation team led by Professor Shen Lin from the Department of Gastrointestinal Oncology of Peking University Cancer Hospital and Institute, as well as the representatives of the ethics institution and the KAEDI team jointly opened and witnessed the historic moment of the clinical trial of KD-496 CAR-T cell injection for the treatment of NKG2DL+/CLDN18.2+ advanced solid tumors. At the kickoff meeting, the clinical investigators gave professional guidance on the development of this project and placed high hopes on it.
KD-496 CAR-T cell injection is the world's first dual-targeted NKG2DLand CLDN18.2CAR-T cell therapy product with independent intellectual property rights of KAEDI. The indications for this trial are advanced solid tumors, mainly gastric and pancreatic cancers. The study was designed as an exploratory trial of open, single-arm clinical study, and the clinical trial was carried out in strict accordance with national GCP regulations to ensure the authenticity and validity of clinical trial data. KAEDI strives to develop more CAR-T cell therapy drugs that are both safe and effective in the field of advanced solid tumor treatment, aiming to bring benefits to the majority of patients with advanced solid tumors.
About KAEDI
KAEDI is a new drug research and development company in the clinical stage that uses leading synthetic biology technologies to develop novel cell therapy drugs for the clinically unmet needs of patients with solid tumors. Relying on its advanced synthetic biology technology platform-KD-SmCAR™, and the dual targeting CAR development platform-KD-ScCAR™. KAEDI has successfully developed a number of first-in-class cell therapy drug development pipelines for malignant solid tumors, including next-generation autologous and allogeneic CAR-T cell therapy pipelines. At present, KAEDI has been declared more than 30 CAR-related patents in CN and US, and 16 patents have been authorized, among which the core pipeline KD-025 and KD-496 patents are the first authorized in CN and US.
The pre-clinical research results of KD-025 CAR-T targeting NKG2DL for Hepatocellular carcinoma, Medulloblastoma and GBM have been successively published in the international authoritative Journal of tumor immunotherapy such as “Journal for ImmunoTherapy of Cancer” and “Cancer Immunology Research”. At the same time, the research results were presented at the American Oncology Clinical Annual Meeting ASCO. At present, KD-025 CAR-T IIT clinical trials are being carried out in well-known clinical centers in China, and many cases have been completed, with no obvious toxic and adverse reactions, and the product is safe and effective. The first domestic CAR-T (KD-025 cell injection) targeting NKG2DL for the treatment of solid tumors IND declaration was approved. At present, KAEDI is negotiating with a number of partners to start KD-025 registration phase I clinical trial, and at the same time, KAEDI is promoting the development of the next generation of new virus vectors for in vivo CAR-T and RNA nucleic acid drugs, which is expected to develop KAEDI into a global leader in cell and nucleic acid drugs in the near future.
KAEDI is headquartered in Nanjing, China. For more information, please visit Nanjing KAEDI Biotherapeutics Co., Ltd. official website:
http:// www.kaedibio.com
Email: business@kaedibio.com